Adrenosterone for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 26 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Adrenosterone may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 12,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed adrenosterone in detail.
, An In Silico Study of Phytochemicals of
Cissus quadrangularis
as Resources for Docking With Main Protease of
SARS COV‐2 and Comparative Analysis, ChemistrySelect, doi:10.1002/slct.74758
ABSTRACT Investigating structurally varied ethnopharmacological scaffolds is still essential for finding long‐lasting inhibitors against SARS‐CoV‐2, despite a great deal of research on synthetic antivirals. Cissus quadrangularis is a well‐known medicinal succulent that is highly prized for its rich therapeutic profile of secondary metabolites. However, its unique multi‐constituent strategy against the essential viral replication enzyme, the main protease (M pro ), is still unknown. By performing a comparative structural screening of phytoconstituents from C. quadrangularis against the catalytically active dimeric form of SARS‐CoV‐2 M pro via docking and simulation analyses, this study filled this knowledge gap. The M pro dimer of COVID‐19 was significantly inhibited by the top ranked phytochemicals of C. quadrangularis viz. luteolin (−7.7 Kcal/mol), quercetin (−7.3 Kcal/mol), kaempferol (−7.2 Kcal/mol), adrenosterone (−7.8 Kcal/mol), resveratrol (−7.0 Kcal/mol), piceatannol (−6.9 Kcal/mol), etc. which had the binding energies indicating their potential for additional in vitro research. These results elucidated the structural and thermodynamic framework behind C. quadrangularis's predicted target interaction, offering a clear computational rationale for prioritizing its specific flavonoid and stilbene components as candidates lead for mandatory future in vitro validation. The molecular docking of M pro dimer of COVID‐19 was visualized using PyMOL and Ligplot.